Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Mutations and promoter methylation status of NPM1 in myeloproliferative disorders.

Literature DB >> 16870548

Mutations and promoter methylation status of NPM1 in myeloproliferative disorders.

Yasuhiro Oki, Jaroslav Jelinek, Miloslav Beran, Srdan Verstovsek, Hagop M Kantarjian, Jean-Pierre J Issa.

Abstract

We determined mutations and promoter methylation status of NPM1 using pyrosequencing in 199 samples of myeloid neoplasia including myeloproliferative disorders (MPD). The mutations were present in 4% of chronic myelomonocytic leukemia, but not in other MPD or myelodysplastic syndromes. Promoter methylation was rare, and was found in only three samples of MPD.

Entities: Disease Gene

Mesh：

Substances：

Year: 2006 PMID： 16870548

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

Keyword Cloud
Cited

8 in total

Review 1. Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity.

Authors: Rachel Rau; Patrick Brown
Journal: Hematol Oncol Date: 2009-12 Impact factor: 5.271

2. NPM1 gene deletions in myelodysplastic syndromes with 5q- and complex karyotype.

Authors: Emanuele Ammatuna; Paola Panetta; Xabier Agirre; Tiziana Ottone; Serena Lavorgna; Maria José Calasanz; Francesco Lo-Coco
Journal: Haematologica Date: 2011-03-10 Impact factor: 9.941

3. Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies.

Authors: Ying Ye; Michael A McDevitt; Mingzhou Guo; Wei Zhang; Oliver Galm; Steven D Gore; Judith E Karp; Jaroslaw P Maciejewski; Jeanne Kowalski; Hua-Ling Tsai; Lukasz P Gondek; Hsing-Chen Tsai; Xiaofei Wang; Craig Hooker; B Douglas Smith; Hetty E Carraway; James G Herman
Journal: Cancer Res Date: 2009-10-13 Impact factor: 12.701

4. Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia.

Authors: Yasuhiro Oki; Jaroslav Jelinek; Lanlan Shen; Hagop M Kantarjian; Jean-Pierre J Issa
Journal: Blood Date: 2007-11-30 Impact factor: 22.113

Review 5. NPM1-Mutated Myeloid Neoplasms with <20% Blasts: A Really Distinct Clinico-Pathologic Entity?

Authors: Fabio Forghieri; Vincenzo Nasillo; Ambra Paolini; Francesca Bettelli; Valeria Pioli; Davide Giusti; Andrea Gilioli; Corrado Colasante; Gloria Acquaviva; Giovanni Riva; Patrizia Barozzi; Rossana Maffei; Leonardo Potenza; Roberto Marasca; Claudio Fozza; Enrico Tagliafico; Tommaso Trenti; Patrizia Comoli; Giuseppe Longo; Mario Luppi
Journal: Int J Mol Sci Date: 2020-11-26 Impact factor: 5.923

Mutations and promoter methylation status of NPM1 in myeloproliferative disorders.

Review 1. Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity.

2. NPM1 gene deletions in myelodysplastic syndromes with 5q- and complex karyotype.

3. Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies.

4. Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia.

Review 5. NPM1-Mutated Myeloid Neoplasms with <20% Blasts: A Really Distinct Clinico-Pathologic Entity?

Review 6. Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives.

7. Mutation analysis of JAK2V617F, FLT3-ITD, NPM1, and DNMT3A in Chinese patients with myeloproliferative neoplasms.

Review 8. The Role of Nucleophosmin 1 (NPM1) Mutation in the Diagnosis and Management of Myeloid Neoplasms.